What did @extraleonardo actually say?
The creator described using BPC-157 and TB-500 together for repeated sports injuries, claiming the combination works "synergistically" through mechanisms including angiogenesis and anti-inflammation. The boldest claim: a grade 2 hamstring tear that had him back to weighted squats "within two to three weeks." He also rattled off a list of other conditions he treated with BPC-157 alone: rotator cuff tears, bursitis, chest tears, ligament injuries, and general inflammation. His conclusion was unambiguous: "It is an amazing peptide."
To be clear, this is anecdotal self-reporting. He is not a clinician, there was no imaging to confirm healing, no control condition, and no way to rule out natural recovery, training modifications, or placebo response. That does not automatically mean he is wrong. It means the claim deserves scrutiny, not a standing ovation.
Does the science back this up?
Partially, and with significant caveats. The preclinical evidence for BPC-157 is genuinely interesting, but almost entirely from animal models. Human trials are sparse to nonexistent for most of these injury claims.
BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a protein found in gastric juice. In rodent studies, it has shown consistent effects on tendon and ligament healing. Sikiric et al. (2018, Current Pharmaceutical Design) documented accelerated tendon-to-bone healing in rats, and separate work by the same group showed upregulation of growth hormone receptor expression in injured tissue. Chang et al. (2011, Journal of Applied Physiology) demonstrated improved Achilles tendon healing in rats treated with BPC-157 compared to controls.
TB-500 (Thymosin Beta-4) has its own modest evidence base. Goldstein et al. (2012, Annals of the New York Academy of Sciences) showed it promotes actin polymerization and cell migration, processes relevant to tissue repair. Synergy between the two peptides is biologically plausible but not yet directly studied in humans.
The honest summary: the mechanisms are real in animals. Whether those mechanisms translate to a human healing a hamstring tear in under three weeks is not established by controlled research.
What did they get wrong (or right)?
He got the mechanism description roughly right. Angiogenesis, the formation of new blood vessels, is one of the better-documented effects of BPC-157 in preclinical work, and it is relevant to tissue repair because injured tendons and ligaments are notoriously hypovascular. Saying the two peptides work "synergistically" is plausible, not fabricated.
What he got wrong, or at least overclaimed, is the leap from his personal experience to implied efficacy. A grade 2 hamstring tear has a typical clinical recovery of 4-8 weeks depending on severity and rehabilitation quality. Some athletes recover faster without any peptides. He provides no baseline comparison, no imaging confirmation of tear severity or resolution, and no accounting for variables like his training background, nutrition, sleep, or physical therapy.
He also lists "chest tears" and "rotator cuff tears" casually, which are serious structural injuries. Implying BPC-157 manages these is a significant claim that the existing literature does not support in humans. That framing should be treated with real skepticism.
What should you actually know?
BPC-157 is not FDA-approved for any indication. It is currently classified by the FDA as a substance that has been withdrawn from consideration for compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which creates a complicated legal landscape for its availability in the United States.
The peptide is not a banned substance by WADA as of the most recent prohibited list update, but that status can change, and athletes in tested sports should verify current status independently.
If you are considering peptide therapy for injury recovery, the responsible path is working with a licensed provider who can review your specific injury, imaging, and medical history. Anecdotes from TikTok, including compelling ones with 30 empty vials as props, are not a substitute for that evaluation. Recovery timelines vary enormously between individuals, and attributing speed of recovery solely to a peptide ignores most of the variables that actually drive healing.
- BPC-157 has no completed Phase 2 or Phase 3 human clinical trials for musculoskeletal injury as of 2024.
- Animal studies use injected BPC-157 directly at or near injury sites, which differs from many self-administration methods described online.
- TB-500 human data is similarly limited, with most evidence coming from wound healing and cardiac models.